BTIG Maintains Buy on AVITA Medical, Raises Price Target to $11
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $7 to $11.
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $7 to $11.